fyodor32768 | 15 points
ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19Retrospective study by the Broward docs using Ivermectin.
https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v1
[-] movethroughit | 1 points
Great results! Perhaps enough to inspire other doctors to try this but certainly seems like enough to justify more RCTs. Would like to have seen viral loads covered, but maybe the data is in there somewhere.
I'm looking forward to the 600mg Ivermectin trial results. I wonder if a vastly higher dose would lead to even better results
[-] IvermectinGuineaPig | 1 points
So, I dont have COVID-19 yet, but I will. We all will. I have already started taking Ivermectin low dosing for about 5 days. I have taken about 20 drops which is 1 ml (.05 ml per drop). That's based on 6 mcg per. That is essentially the dose to give a 100 lbs pig. I weigh 225 lbs. I am going to freeze at this dose and when I get, again when not if because we are all gonna get it, I am going to do a Stat dose of 100 drops for 2 days which is about 5 ml x 2= 10 ml. I measure my temp a few times a day because I wanna catch it early. I live in Arizona, I wear a mask in public (sometimes). I am 55 years old and am in good health. I believe it is the Cytokine Storm that needs to be prevented and that COVID itself is not the killer. I have a degree in Chemistry, Engineering, and Law. I worked on Legionnaire's Disease at FSU back in the 80s but that was an Amoeba converting to a Parmecium clogging the brain. A parasite as well but COVID attacks the lungs as we all know and is a virus. Gotta stop the replication before it stops you. Ya dont kill a virus you disable a virus. It has to be turned off and if the word out there is right Ivermectin an Animal dewormer you can get for 30 bucks in Amazon does the trick. Not gonna get into Big Farma and the media playing it down ala Hydrixychloroquin. Just gonna play it straight. If Ifeel bad, have a temp gonna stat dose and measure my temp and share.
In any event, I will post and you can follow and let's see what happens.
[-] fyodor32768 | 1 points | Jun 09 2020 14:42:10
Abstract
Abstract Importance: No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective: To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting: Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants: 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure: Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures: The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results: Univariate analysis showed lower mortality in the ivermectin group (25.2% versus 15.0%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance: Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings require randomized controlled trials for confirmation.
permalink